Related Experiment Videos
Pharmacokinetic aspects of caffeine in premature infants with apnoea
Insights
Caffeine treatment for apnea in premature infants showed very slow clearance and prolonged half-life. Monitoring blood caffeine levels is crucial to prevent toxicity in these vulnerable infants.
Area of Science:
- Neonatal Pharmacology
- Pediatric Pharmacokinetics
Background:
- Apnea of prematurity is a common respiratory challenge in neonates.
- Caffeine is a widely used stimulant for treating apnea of prematurity.
Purpose of the Study:
- To characterize the pharmacokinetics of caffeine in premature infants.
- To determine the relationship between caffeine dosage, plasma concentrations, and clinical response in neonates.
Main Methods:
- Pharmacokinetic analysis of caffeine in 13 premature infants.
- Intravenous (IV) and oral (PO) administration of caffeine (15 mg/kg doses).
- Measurement of plasma caffeine concentrations and calculation of clearance (Clb), half-life (t1/2), and volume of distribution (Vd).
Main Results:
- Extremely slow caffeine clearance (Clb: 8.5 ml/kg/h) and prolonged half-life (t1/2: 65.0 h) were observed.
- Volume of distribution (Vd) was 0.78 L/kg.
- Effective plasma concentrations varied widely (12-36 µg/mL) and overlapped with subtherapeutic levels.
- No significant correlation between pharmacokinetic parameters and postnatal age was found.
Conclusions:
- Single doses of caffeine effectively managed apnea in most premature infants.
- Close monitoring of infant blood caffeine levels is essential to avoid toxicity, especially with repeated dosing.
- Individualized dosing and therapeutic drug monitoring are recommended for safe and effective caffeine therapy in neonates.
Abstract:
The pharmacokinetics of caffeine was examined in 13 premature infants (gestational age 25-34 weeks, birth weight 920-2060 g, postnatal age 1-42 days) who received the drug for treatment of apnoea. Caffeine (1% aqueous solution) was given i.v. in single doses: guided by the clinical response infants received between one and seven (mean 2.6) doses of 15 mg/kg. Mean (+/- SE; range) Clb was extremely slow - 8.5 ml/kg/h (+/- 0.4; 5.8-12.2), t1/2 was prolonged - 65.0 h (+/- 3.7; 48.2-87.5 h) and Vd was 0.781/kg(+/- 0.04; 0.47-1.01). No significant correlation was found between Clb, t1/2 and postnatal age in the whole group or in individual infants. Effective plasma concentrations varied over a wide range (12-36 micrograms/ml) and overlapped with subtherapeutic concentrations (less than or equal to 24 micrograms/ml). Single doses of 15 mg/kg i.v. or p.o. prevented apnoea in most cases, if necessary followed by additional doses. Monitoring the blood level of caffeine in infants receiving frequent repeated doses is necessary to prevent toxicity.